

CITATION REPORT

List of articles citing

SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants

DOI: 10.1017/s1092852900019726
CNS Spectrums, 2005, 10, 732-47.

Source: <https://exaly.com/paper-pdf/37981103/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
380	Neurotransmitters. 45-142		1
379	Tiagabine in anxiety disorders. 2006 , 7, 1977-87		34
378	Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities. 2006 , 7, 198-222		37
377	Differential blockade of nerve injury-induced shift in weight bearing and thermal and tactile hypersensitivity by milnacipran. 2006 , 7, 513-20		37
376	A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerability. <i>Journal of Clinical Psychopharmacology</i> , 2006 , 26, 482-8	1.7	65
375	Duloxetine in the management of depression. 2006 , 1, 713-720		
374	Neonatal seizures from in utero venlafaxine exposure. 2006 , 42, 737-8		22
373	Serotonin and norepinephrine reuptake inhibition and eating behavior. 2006 , 1083, 252-69		61
372	Antidepressant use in ambulatory cancer patients. 2006 , 8, 275-81		15
371	New and future migraine therapy. 2006 , 112, 199-212		62
370	Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. 2006 , 318, 657-65		247
369	Serotonin noradrenaline reuptake inhibitors: Logical evolution of antidepressant development. 2006 , 10 Suppl 2, 5-11		11
368	Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. 2007 , 334, 242		65
367	Charles Bonnet Syndrome: successful treatment of visual hallucinations due to vision loss with selective serotonin reuptake inhibitors. 2007 , 21, 553-5		39
366	QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. 2007 , 49, 146-53		51
365	Hypertension induced by regular doses of milnacipran: a case report. 2007 , 40, 41-2		6
364	Desvenlafaxine succinate identifies novel antagonist binding determinants in the human norepinephrine transporter. 2007 , 323, 720-9		12

363	Efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. 2007 , 2, 361-371		1
362	Venlafaxine ingestion is associated with rhabdomyolysis in adults: a case series. 2007 , 32, 97-101		42
361	Analysis of the rate of improvement of specific psychic and somatic symptoms of general anxiety disorder during long-term treatment with venlafaxine ER. <i>CNS Spectrums</i> , 2007 , 12, 703-11	1.8	18
360	Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial. 2007 , 22, 167-74		166
359	Delivery outcome in relation to maternal use of some recently introduced antidepressants. <i>Journal of Clinical Psychopharmacology</i> , 2007 , 27, 607-13	1.7	89
358	Discriminative stimulus properties of the selective norepinephrine reuptake inhibitor, reboxetine, in rats: a characterization with alpha/beta-adrenoceptor subtype selective ligands, antidepressants, and antagonists at neuropeptide receptors. <i>International Journal of Neuropsychopharmacology</i> , 2007 , 10, 573-83	5.8	9
357	Antidepressant medications and other treatments of depressive disorders: a CINP Task Force report based on a review of evidence. <i>International Journal of Neuropsychopharmacology</i> , 2007 , 10 Suppl 1, S1-207	5.8	37
356	A case of adult attention-deficit/hyperactivity disorder alleviated by milnacipran. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2007 , 31, 772-5	5.5	4
355	Novel therapeutic approaches in IBS. 2007 , 7, 598-604		13
354	Concerted action of antiepileptic and antidepressant agents to depress spinal neurotransmission: Possible use in the therapy of spasticity and chronic pain. 2007 , 50, 642-52		11
353	Apport des ISRS et IRSNA dans l'anxiodépression. 2007 , 33, 699-700		
352	Duloxetine: a review of its use in the treatment of major depressive disorder. 2007 , 21, 581-609		50
351	An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. 2007 , 30, 437-55		97
350	A Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. 2007 , 62, 1149-54		120
349	Dual Selective Serotonin and Norepinephrine Reuptake Inhibitors (SSNRIs) for Depression. 197-213		
348	Triple uptake inhibitors: therapeutic potential in depression and beyond. 2007 , 16, 1365-77		90
347	Chapter 2 Recent Developments in Monoamine Reuptake Inhibitors. 2007 , 13-26		16
346	. 2007 ,		34

345	Synthesis of enantiomerically pure milnacipran analogs and inhibition of dopamine, serotonin, and norepinephrine transporters. 2007 , 17, 2834-7		24
344	Management of musculoskeletal pain. 2007 , 21, 153-66		77
343	Pharmacological characterization of JNJ-28583867, a histamine H(3) receptor antagonist and serotonin reuptake inhibitor. <i>European Journal of Pharmacology</i> , 2007 , 576, 43-54	5:3	39
342	Differentiating antidepressants of the future: efficacy and safety. 2007 , 113, 134-53		132
341	Relationship of brainstem raphe echogenicity and clinical findings in depressive states. 2007 , 155, 67-73		55
340	Psychopharmacology of anxiety. 2007 , 6, 143-148		6
339	Effects of milnacipran and fluvoxamine on hyperemotional behaviors and the loss of tryptophan hydroxylase-positive cells in olfactory bulbectomized rats. 2007 , 191, 857-65		30
338	Troubles sexuels au cours des traitements antidépresseurs lors de leur utilisation dans les cancers gynécologiques. 2007 , 1, 279-281		0
337	Medically serious adverse effects of newer antidepressants. 2008 , 10, 249-57		23
336	Influence of the tyrosine hydroxylase val81met polymorphism and catechol-O-methyltransferase val158met polymorphism on the antidepressant effect of milnacipran. 2008 , 23, 121-8		48
335	Resolution of sexual dysfunction during acute treatment of major depression with milnacipran. 2008 , 23, 527-32		22
334	Studies on the SAR and pharmacophore of milnacipran derivatives as monoamine transporter inhibitors. 2008 , 18, 1346-9		14
333	The Design, Synthesis and Structure-Activity Relationship of Mixed Serotonin, Norepinephrine and Dopamine Uptake Inhibitors. 2008 , 131-154		1
332	Screening of venlafaxine hydrochloride for transdermal delivery: passive diffusion and iontophoresis. 2008 , 9, 791-7		21
331	Inhibition of uptake 2 (or extraneuronal monoamine transporter) by normetanephrine potentiates the neurochemical effects of venlafaxine. 2008 , 1203, 68-78		16
330	Pharmacological treatments of fibromyalgia: do complex conditions need complex therapies?. 2008 , 13, 333-40		17
329	A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder. 2008 , 42, 22-34		54
328	Evidence-informed management of chronic low back pain with adjunctive analgesics. 2008 , 8, 21-7		14

327	Characterization of thien-2-yl 1S,2R-milnacipran analogues as potent norepinephrine/serotonin transporter inhibitors for the treatment of neuropathic pain. 2008 , 51, 7265-72		8
326	Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. 2008 , 8, 1787-97		13
325	Successful duloxetine use to prevent venlafaxine withdrawal symptoms. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2008 , 32, 576	5.5	1
324	Change in pain severity with open label venlafaxine use in patients with a depressive symptomatology: an observational study in primary care. 2008 , 23, 178-86		8
323	Antidepressants as analgesics. 2008 , 22, 139-56		59
322	Pharmacological management of neuropathic pain following spinal cord injury. 2008 , 22, 455-75		115
321	Use of Atomoxetine in a Patient with Fibromyalgia Syndrome and Attention-Deficit Hyperactivity Disorder. 2008 , 16, 189-192		2
320	Effects of milnacipran and paroxetine on overactive bladder due to neurologic diseases: a urodynamic assessment. 2008 , 81, 335-9		21
319	The under-recognized role of dopamine in the treatment of major depressive disorder. 2008 , 23, 63-9		23
318	Clinical evidence for serotonin and norepinephrine reuptake inhibition of duloxetine. 2008 , 23, 161-9		37
317	Everyday problems in treating depression: focus on SNRIs. Introduction. <i>CNS Spectrums</i> , 2008 , 13, 4	1.8	1
316	The role of duloxetine in the treatment of anxiety disorders. <i>Neuropsychiatric Disease and Treatment</i> , 2008 , 4, 929-35	3.1	7
315	Treatment options and patient perspectives in the management of fibromyalgia: future trends. <i>Neuropsychiatric Disease and Treatment</i> , 2008 , 4, 1059-71	3.1	24
314	Influence of serotonergic/noradrenergic gene polymorphisms on nausea and sweating induced by milnacipran in the treatment of depression. <i>Neuropsychiatric Disease and Treatment</i> , 2009 , 5, 393-8	3.1	6
313	Duloxetine for the management of fibromyalgia syndrome. <i>Journal of Pain Research</i> , 2009 , 99	2.9	1
312	Introduction: selecting an antidepressant. <i>CNS Spectrums</i> , 2009 , 14, 4-7	1.8	1
311	Duloxetine in the treatment of generalized anxiety disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2008 , 4, 1169-80	3.1	7
310	Effect of milnacipran on suicidality in patients with mild to moderate depressive disorder. <i>Neuropsychiatric Disease and Treatment</i> , 2009 , 5, 415-20	3.1	4

309	Advances in diagnostic and treatment options in patients with fibromyalgia syndrome. 2009 , 1, 193-209		2
308	Impact of drug tolerability on the selection of antidepressant treatment in patients with major depressive disorder. <i>CNS Spectrums</i> , 2009 , 14, 8-14	1.8	14
307	A symptom-based approach to pharmacologic management of fibromyalgia. 2009 , 5, 191-9		47
306	Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. 2009 , 23, 531-8		38
305	Fibromyalgia: a new treatment option for fibromyalgia. 2009 , 5, 188-90		3
304	Depression and related disorders during the female reproductive cycle. 2009 , 5, 577-87		12
303	The effect of melatonergic and non-melatonergic antidepressants on sleep: weighing the alternatives. 2009 , 10, 342-54		15
302	The efficacy and safety of milnacipran for treatment of fibromyalgia. a randomized, double-blind, placebo-controlled trial. 2009 , 36, 398-409		210
301	Depression as a Comorbidity to Diabetes: Implications for Management. 2009 , 5, 523-535		7
300	Noradrenergic and serotonergic mechanisms in the neurobiology of posttraumatic stress disorder and resilience. 2009 , 1293, 13-23		176
299	Use of latency to immobility improves detection of antidepressant-like activity in the behavioral despair test in the mouse. <i>European Journal of Pharmacology</i> , 2009 , 616, 128-33	5.3	96
298	Duloxetine in acute major depression: review of comparisons to placebo and standard antidepressants using dissimilar methods. 2009 , 24, 177-90		51
297	Functional magnetic resonance imagery (fMRI) in fibromyalgia and the response to milnacipran. 2009 , 24 Suppl 1, S19-23		18
296	Fibromyalgia--pathways and neurotransmitters. 2009 , 24 Suppl 1, S11-7		36
295	The Cochrane library and the treatment of major depression in children and youth: an overview of reviews. 2009 , 4, 1336-1350		
294	Automated determination of venlafaxine in human plasma by on-line SPE-LC-MS/MS. Application to a bioequivalence study. 2009 , 32, 637-43		12
293	Symptoms of delusion: the effects of discontinuation of low-dose venlafaxine. 2009 , 120, 329-31		7
292	Differential inhibitory effects of drugs acting at the noradrenaline and 5-hydroxytryptamine transporters in rat and human neocortical synaptosomes. 2009 , 158, 1848-56		16

291	[Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study]. 2009 , 35, 595-604		2
290	Pathophysiological basis of migraine prophylaxis. 2009 , 89, 176-92		84
289	Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors. 2009 , 122, S44-55		36
288	The effects of serotonin and/or noradrenaline reuptake inhibitors on impulsive-like action assessed by the three-choice serial reaction time task: a simple and valid model of impulsive action using rats. 2009 , 20, 474-83		40
287	Sexual dysfunction, depression, and the impact of antidepressants. <i>Journal of Clinical Psychopharmacology</i> , 2009 , 29, 157-64	1.7	212
286	Improvement of selective serotonin reuptake inhibitor-induced sexual dysfunction without worsening of depressive symptom after switching to milnacipran. <i>Clinical Neuropharmacology</i> , 2009 , 32, 177-8	1.4	1
285	Role of serotonin 5-HT _{1A} receptors in the antidepressant-like effect and the antinociceptive effect of venlafaxine in mice. <i>International Journal of Neuropsychopharmacology</i> , 2009 , 12, 61-71	5.8	36
284	Factors that impact choice of antidepressant treatment in medically complex patients. <i>CNS Spectrums</i> , 2009 , 14, 20-7	1.8	1
283	Variation in the risk of suicide attempts and completed suicides by antidepressant agent in adults: a propensity score-adjusted analysis of 9 years' data. 2010 , 67, 497-506		54
282	Milnacipran-associated urinary retention: a case report. <i>Journal of Clinical Psychopharmacology</i> , 2010 , 30, 641	1.7	5
281	In vivo canine model comparison of cardiovascular effects of antidepressants milnacipran and imipramine. 2010 , 10, 275-82		11
280	Withdrawal from fixed-dose injection of methamphetamine decreases cerebral levels of 3-methoxy-4-hydroxyphenylglycol and induces the expression of anxiety-related behavior in mice. 2010 , 35, 749-60		23
279	Influence of ligand binding kinetics on functional inhibition of human recombinant serotonin and norepinephrine transporters. 2010 , 61, 192-204		25
278	Somatic symptoms: an important index in predicting the outcome of depression at six-month and two-year follow-up points among outpatients with major depressive disorder. 2010 , 125, 134-40		28
277	Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. 2010 , 9, 628-42		251
276	Association between Antidepressant Use during Pregnancy and Infants Born Small for Gestational Age. 2010 , 55, 643-652		30
275	Milnacipran: a unique antidepressant?. <i>Neuropsychiatric Disease and Treatment</i> , 2010 , 6, 23-31	3.1	18
274	Duloxetine: a review of its safety and efficacy in the management of fibromyalgia syndrome. 2010 , 2, 57-72		3

273	Treatment of patients with comorbid depression and diabetes with metformin and milnacipran. <i>Neuropsychiatric Disease and Treatment</i> , 2010 , 9	3.1	78
272	Antidepressant therapy with milnacipran and venlafaxine. <i>Neuropsychiatric Disease and Treatment</i> , 2010 , 17	3.1	1
271	Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study. <i>Neuropsychiatric Disease and Treatment</i> , 2010 , 71	3.1	1
270	Suicidality: risk factors and the effects of antidepressants. The example of parallel reduction of suicidality and other depressive symptoms during treatment with the SNRI, milnacipran. <i>Neuropsychiatric Disease and Treatment</i> , 2010 , 6, 3-8	3.1	6
269	Improvement of social adaptation in depression with serotonin and norepinephrine reuptake inhibitors. <i>Neuropsychiatric Disease and Treatment</i> , 2010 , 6, 647-55	3.1	17
268	New and emerging therapeutic agents for the treatment of fibromyalgia: an update. <i>Journal of Pain Research</i> , 2010 , 3, 89-103	2.9	19
267	Absence of sibutramine effect on spontaneous anxiety in rats. 2010 , 54, 375-80		7
266	Milnacipran: a selective serotonin and norepinephrine dual reuptake inhibitor for the management of fibromyalgia. 2010 , 2, 201-20		2
265	Venlafaxine-associated nocturnal bruxism in a depressive patient successfully treated with buspirone. 2010 , 24, 627-8		23
264	Drug Interactions with St. John's Wort. 2010 , 273-290		
263	Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. 2010 , 24, 1209-16		41
262	Comparison of milnacipran, duloxetine and pregabalin in the formalin pain test and in a model of stress-induced ultrasonic vocalizations in rats. 2010 , 66, 135-40		31
261	Physician speciality and pain reduction in patients with depressive symptoms under treatment with venlafaxine. 2010 , 25, 455-60		0
260	Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. 2011 , 27, 1089-96		6
259	Diagnosis and treatment of major depressive disorder. 2011 , 29, 177-93, ix		26
258	Monoaminergic Antidepressants in the Relief of Pain: Potential Therapeutic Utility of Triple Reuptake Inhibitors (TRIs). 2011 , 4, 285-342		19
257	[Cardiogenic shock after venlafaxine poisoning]. 2011 , 30, 857-8		5
256	Comorbidities and factors related to discontinuation of pharmacotherapy among outpatients with major depressive disorder. 2011 , 52, 370-7		16

255	It might be a big family but the pain remains-last chance saloon for selective 5-HT receptor ligands?. 2011 , 11, 39-44		8
254	Adverse reactions to duloxetine in depression. 2011 , 10, 839-50		19
253	Balance control improves following replacement of paroxetine with venlafaxine and levodopa in a case of microvascular dementia. 2011 , 9, 133-7		2
252	Depression in vascular pathologies: the neurologist's point of view. 2011 , 7, 433-43		6
251	The noradrenergic symptom cluster: clinical expression and neuropharmacology. <i>Neuropsychiatric Disease and Treatment</i> , 2011 , 7, 15-20	3.1	28
250	Improvement of the noradrenergic symptom cluster following treatment with milnacipran. <i>Neuropsychiatric Disease and Treatment</i> , 2011 , 7, 21-7	3.1	11
249	Pharmacotherapy for fibromyalgia. 2011 , 2, 17		12
248	Biopsychosocial model of irritable bowel syndrome. 2011 , 17, 131-9		172
247	Inhibition of G protein-activated inwardly rectifying K ⁺ channels by different classes of antidepressants. <i>PLoS ONE</i> , 2011 , 6, e28208	3.7	25
246	Serotonin/norepinephrine inhibitors: pharmacological profile. 2011 , 9, 350-352		
245	PharmGKB summary: citalopram pharmacokinetics pathway. 2011 , 21, 769-72		36
244	Duloxetine as adjunctive treatment to clozapine in patients with schizophrenia: a randomized, placebo-controlled trial. 2011 , 26, 303-10		28
243	GCH1, BH4 and pain. 2011 , 12, 1728-41		41
242	A systematic review of duloxetine and venlafaxine in major depression, including unpublished data. 2011 , 123, 247-65		50
241	Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain. <i>European Journal of Pharmacology</i> , 2011 , 655, 46-51	5.3	44
240	Triple reuptake inhibitors for treating subtypes of major depressive disorder: the monoamine hypothesis revisited. 2011 , 20, 1107-30		71
239	Anxiety trait in patients with stress-induced cardiomyopathy: a case-control study. 2011 , 100, 523-9		42
238	Fatal venlafaxine poisonings are associated with a high prevalence of drug interactions. 2011 , 125, 349-58		19

237	Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. 2011 , 215, 367-77		22
236	Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder. 2011 , 11, 19		10
235	Duloxetine in the acute and continuation treatment of major depressive disorder. 2011 , 11, 1525-39		
234	Duloxetine in the treatment of depression: an overview. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2011 , 11, 174-83	1.8	5
233	The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition. 2011 , 25, 1357-64		15
232	Halothane-anesthetized rabbit: a new experimental model to test the effects of besipirdine and duloxetine on lower urinary tract function. 2011 , 86, 210-9		3
231	Treatment with duloxetine in adults and the incidence of cardiovascular events. <i>Journal of Clinical Psychopharmacology</i> , 2012 , 32, 23-30	1.7	11
230	Evidence-based pharmacotherapy of post-traumatic stress disorder (PTSD). <i>International Journal of Neuropsychopharmacology</i> , 2012 , 15, 825-40	5.8	127
229	Pain in spinal cord injury. 2012 , 2, 87-94		11
228	Antidepressant Pharmacology: Introduction for the Pharmacy Technician. 2012 , 28, 26-32		
227	Glucose metabolism and antidepressant medication. 2012 , 18, 5900-19		39
226	Evidence-based pharmacotherapy of post-traumatic stress disorder. 171-189		
225	Antidepressants and Sleep: Neurophysiology and Clinical Correlates. 2012 , 8, 2-13		
224	Für jeden Patienten den optimalen Wirkstoff finden. 2012 , 23, 26-38		1
223	Contemporary concepts in the pharmacotherapy of depression in older people. 2012 , 145, 128-135.e2		3
222	High-dose desvenlafaxine in outpatients with major depressive disorder. <i>CNS Spectrums</i> , 2012 , 17, 121-30.8		7
221	Miscellaneous central nervous system intoxicants. 2012 , 28, 587-600		1
220	Elevated risk of preeclampsia in pregnant women with depression: depression or antidepressants?. 2012 , 175, 988-97		71

219	The hidden third: improving outcome in treatment-resistant depression. 2012 , 26, 587-602	49
218	A Practical Kilogram-Scale Process to a Milnacipran Analogue, N,N-Diallyl (1R, 2R)-2-(Aminomethyl)-1-(2-thienyl)cyclopropanecarboxamide. 2012 , 16, 2021-2024	3
217	5-HT(3) receptor mediates the dose-dependent effects of citalopram on pentylenetetrazole-induced clonic seizure in mice: involvement of nitric oxide. 2012 , 101, 217-27	35
216	The role of the NMDA receptors and l-arginine-nitric oxide-cyclic guanosine monophosphate pathway in the antidepressant-like effect of duloxetine in the forced swimming test. 2012 , 103, 408-17	27
215	Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside. 2012 , 136, 343-53	30
214	Screening, diagnosis, and treatment of depression. 2012 , 177, 60-6	6
213	Duloxetine in the management of chronic musculoskeletal pain. 2012 , 8, 267-77	25
212	The feasibility study of transdermal drug delivery systems for antidepressants possessing hydrophilicity or hydrophobicity. 2012 , 42, 109-114	6
211	The effects of serotonin/norepinephrine reuptake inhibitors and serotonin receptor agonist on morphine analgesia and tolerance in rats. 2012 , 62, 317-23	28
210	Duloxetine improves oxaliplatin-induced neuropathy in patients with colorectal cancer: an open-label pilot study. 2012 , 20, 1491-7	46
209	Negative impact of migraine on quality of life after 4 weeks of treatment in patients with major depressive disorder. 2012 , 66, 8-16	7
208	Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation. 2012 , 89, 72-9	99
207	Apathy in currently nondepressed patients treated with a SSRI for a major depressive episode: outcomes following randomized switch to either duloxetine or escitalopram. 2012 , 46, 667-74	20
206	Translational investigation and treatment of neuropathic pain. 2012 , 8, 15	38
205	Milnacipran enhances the control of impulsive action by activating DR-like receptors in the infralimbic cortex. 2013 , 225, 495-504	14
204	Diabetic neuropathies: diagnosis and management. 2013 , 98, 267-80	109
203	Neuropathic pain in cancer. 2013 , 111, 105-11	169
202	Safety and tolerability of levomilnacipran ER in major depressive disorder: results from an open-label, 48-week extension study. 2013 , 33, 761-71	25

201	Towards a mechanism-based approach to pain management in osteoarthritis. 2013 , 9, 654-64		182
200	Does adding noradrenaline reuptake inhibition to selective serotonin reuptake inhibition improve efficacy in patients with depression? A systematic review of meta-analyses and large randomised pragmatic trials. 2013 , 27, 740-58		25
199	Levomilnacipran for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antidepressant--what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. 2013 , 67, 1089-104		104
198	Influence of Duloxetine on the in-vivo pharmacokinetics of Metoprolol in rat model. 2013 , 7, 362-366		1
197	Neuronal and immunological basis of action of antidepressants in chronic pain - clinical and experimental studies. 2013 , 65, 1611-21		79
196	Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety. <i>Neuropharmacology</i> , 2013 , 70, 338-47	5.5	142
195	Side effects of antidepressants during long-term use in a naturalistic setting. 2013 , 23, 1443-51		132
194	Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosa. 2013 , 48, 195-201		70
193	The Role of Antidepressants in the Treatment of Chronic Pain. 2013 , 45-51		2
192	Might different cytokine trends in depressed patients receiving duloxetine indicate differential biological backgrounds. 2013 , 145, 300-7		42
191	Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor. 2013 , 4, 560-4		10
190	Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor. 2013 , 23, 728-41		41
189	Effects of milnacipran on cognitive flexibility following chronic stress in rats. <i>European Journal of Pharmacology</i> , 2013 , 703, 62-6	5.3	17
188	The Effect of Antidepressant Therapy on Blood Pressure and Heart Rate Variability. 2013 , 48, 1-7		0
187	A translational pharmacology approach to understanding the predictive value of abuse potential assessments. 2013 , 24, 410-36		43
186	The Effect of Antidepressant Therapy on Blood Pressure and Heart Rate Variability. 2013 , 48, 8		
185	A review of the adverse effects and safety of noradrenergic antidepressants. 2013 , 27, 732-9		40
184	Changes in cardiovascular function after venlafaxine but not pregabalin in healthy volunteers: a double-blind, placebo-controlled study of orthostatic challenge, blood pressure and heart rate. 2013 , 28, 562-75		10

183	Liquid chromatography tandem mass spectrometry method for the simultaneous stereoselective determination of venlafaxine and its major metabolite, O-desmethylvenlafaxine, in human plasma. 2013 , 27, 622-35		5
182	Investigating the roles of different monoamine transmitters and impulse control using the 5-choice serial reaction time task. 2013 , 27, 213-21		21
181	Chronic effects of antidepressants on serotonin release in rat raphe slice cultures: high potency of milnacipran in the augmentation of serotonin release. <i>International Journal of Neuropsychopharmacology</i> , 2013 , 16, 2295-306	5.8	8
180	Mirtazapine provokes periodic leg movements during sleep in young healthy men. 2013 , 36, 661-9		31
179	Double-blind, comparative study of milnacipran and paroxetine in Japanese patients with major depression. <i>Neuropsychiatric Disease and Treatment</i> , 2013 , 9, 555-65	3.1	2
178	PSYCHOLOGICAL INTERVENTION INCLUDING EMOTIONAL FREEDOM TECHNIQUES FOR AN ADULT WITH MOTOR VEHICLE ACCIDENT RELATED POSTTRAUMATIC STRESS DISORDER: A CASE STUDY. 2014 , 5, 40-63		1
177	The Combination of Antidepressant Duloxetine with Piracetam in Mice does not Produce Enhancement of Nootropic Activity. 2014 , 23, 224-30		2
176	Levomilnacipran: a newly approved drug for treatment of major depressive disorder. 2014 , 7, 137-45		18
175	Antidepressants as Analgesics. 2014 , 530-542.e4		4
174	Venlafaxine pharmacokinetics focused on drug metabolism and potential biomarkers. 2014 , 29, 129-41		24
173	Levomilnacipran ER 40 mg and 80 mg in patients with major depressive disorder: a phase III, randomized, double-blind, fixed-dose, placebo-controlled study. 2014 , 39, 40-9		52
172	Suicidal ideation and behavior associated with antidepressant medications: Implications for the treatment of chronic pain. 2014 , 155, 2471-2475		4
171	A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. <i>Journal of Clinical Psychopharmacology</i> , 2014 , 34, 47-56	1.7	61
170	Synergistic regulation of glutamatergic transmission by serotonin and norepinephrine reuptake inhibitors in prefrontal cortical neurons. 2014 , 289, 25177-85		15
169	Prenatal desvenlafaxine induced behavioural alterations in Swiss albino mice. 2014 , 21, 19-21		2
168	Shuganjieyu capsule for major depressive disorder (MDD) in adults: a systematic review. 2014 , 18, 941-53		14
167	The prevalence of duloxetine in medico-legal death investigations in Victoria, Australia (2009-2012). 2014 , 234, 165-73		5
166	Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depression. 2014 , 48, 1-12		119

165	Venlafaxine alters microvascular perfusion, $[\alpha_1]$ -beta-CIT binding and BDI scores in flushing postmenopausal women. 2014 , 77, 267-73		3
164	There are no randomized controlled trials that support the United States Preventive Services Task Force Guideline on screening for depression in primary care: a systematic review. 2014 , 12, 13		68
163	Residual symptoms related to physical and panic symptoms at baseline predict remission of depression at follow-up. 2014 , 47, 51-6		5
162	Insights into direct nose to brain delivery: current status and future perspective. 2014 , 21, 75-86		183
161	Levomilnacipran (Fetzima): A New Serotonin-Norepinephrine Reuptake Inhibitor for the Treatment of Major Depressive Disorder. 2014 , 27, 389-95		8
160	A multivariate approach linking reported side effects of clinical antidepressant and antipsychotic trials to in vitro binding affinities. 2014 , 24, 1463-74		13
159	Augmentation of antidepressant effects of duloxetine and bupropion by caffeine in mice. 2014 , 124, 238-44		29
158	Evaluation of blood pressure and heart rate in patients with hypertension who received tapentadol extended release for chronic pain: a post hoc, pooled data analysis. 2014 , 34, 565-76		13
157	Spinal cord injury pain. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2014 , 25, 397-410	2.3	23
156	A randomized, double-blind, placebo-controlled study of flexible doses of levomilnacipran ER (40-120 mg/day) in patients with major depressive disorder. 2014 , 3, 10-9		30
155	Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. 2015 , 14, 119-36		432
154	Depressive Disorders: Major Depressive Disorder and Persistent Depressive Disorder. 2015 , 902-965		
153	Antidepressants. 2015 , 1-4		
152	Pain management in military trauma. 2015 , 27, 235-46		1
151	Biogenic Amines and the Amino Acids GABA and Glutamate: Relationships with Pain and Depression. 2015 , 30, 67-79		26
150	Efficacy of Venlafaxine (Velaxin) in the Treatment of Depression: Results of Recent Trials. 2015 , 45, 576-578		
149	Increased brain uptake of venlafaxine loaded solid lipid nanoparticles by overcoming the efflux function and expression of P-gp. 2015 , 38, 1325-35		15
148	The many different faces of major depression: it is time for personalized medicine. <i>European Journal of Pharmacology</i> , 2015 , 753, 88-104	5.3	36

147	Selective Serotonin Reuptake Inhibitors and Night Sweats in a Primary Care Population. 2015 , 2, 29-33		1
146	Effects of desvenlafaxine on blood pressure in patients treated for major depressive disorder: a pooled analysis. 2015 , 31, 809-20		5
145	Neuropathic Pain due to Small Fiber Neuropathy in Aging: Current Management and Future Prospects. 2015 , 32, 611-21		19
144	Design and synthesis of 4-benzylpiperidine carboxamides as dual serotonin and norepinephrine reuptake inhibitors. 2015 , 23, 6418-26		11
143	Levomilnacipran Pharmacokinetics in Healthy Volunteers Versus Patients with Major Depressive Disorder and Implications for Norepinephrine and Serotonin Reuptake Inhibition. 2015 , 37, 2059-70		8
142	Discovery and SAR study of 3-(tert-butyl)-4-hydroxyphenyl benzoate and benzamide derivatives as novel farnesoid X receptor (FXR) antagonists. 2015 , 23, 6427-36		6
141	Cardiovascular adverse reactions during antidepressant treatment: a drug surveillance report of German-speaking countries between 1993 and 2010. <i>International Journal of Neuropsychopharmacology</i> , 2014 , 18,	5.8	44
140	A brief history of the development of antidepressant drugs: from monoamines to glutamate. 2015 , 23, 1-21		216
139	Treatment of Chronic Pain by Medical Approaches. 2015 ,		
138	Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. 2015 , 13, 42-50.e3		105
137	The Role of Levomilnacipran in the Management of Major Depressive Disorder: A Comprehensive Review. 2016 , 14, 191-9		12
136	Psychological Factors and Conditioned Pain Modulation: A Meta-Analysis. 2016 , 32, 541-54		83
135	Duloxetine in treating generalized anxiety disorder in adults: A meta-analysis of published randomized, double-blind, placebo-controlled trials. 2016 , 8, 215-25		6
134	Empirically Supported Use of Psychiatric Medications in Adolescents and Adults with IBD. 2016 , 22, 1509-22		22
133	[Antidepressant and tolerance: Determinants and management of major side effects]. 2016 , 42, 553-561		27
132	Centrally Targeted Pharmacotherapy for Chronic Abdominal Pain: Understanding and Management. 2017 , 239, 417-440		5
131	Antidepressant Use and Subclinical Measures of Atherosclerosis: The Multi-Ethnic Study of Atherosclerosis. <i>Journal of Clinical Psychopharmacology</i> , 2016 , 36, 340-6	1.7	5
130	Ischemic Colitis as a Complication of Medication Use: An Analysis of the Federal Adverse Event Reporting System. 2016 , 61, 2655-65		17

129	Antidepressant use during pregnancy and risk of postpartum hemorrhage: A systematic review and meta-analysis. 2016 , 83, 160-167		18
128	Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder: A Double-Blind Controlled Clinical Trial. <i>Journal of Clinical Psychopharmacology</i> , 2016 , 36, 720-723	1.7	6
127	An 11-year retrospective review of venlafaxine ingestion in children from the California Poison Control System. 2016 , 35, 767-74		5
126	Combination treatment of fingolimod with antidepressants in relapsing-remitting multiple sclerosis patients with depression: a multicentre, open-label study - REGAIN. 2016 , 9, 378-88		10
125	Role of Collagen Conduit With Duloxetine and/or Pregabalin in the Management of Partial Peripheral Nerve Injury. 2016 , 74, 1120-30		10
124	Intranasal delivery of venlafaxine loaded nanostructured lipid carrier: Risk assessment and QbD based optimization. 2016 , 33, 37-50		34
123	MC11C4: a pilot randomized, placebo-controlled, double-blind study of venlafaxine to prevent oxaliplatin-induced neuropathy. 2016 , 24, 1071-8		36
122	Enantioselective disposition of venlafaxine and its metabolite o-desmethylvenlafaxine in rats. 2017 , 2, 39-45		
121	Pharmacokinetic profiles contribute to the differences in behavioral pharmacology of 071031B enantiomers as novel serotonin and norepinephrine reuptake inhibitors. 2017 , 31, 377-386		2
120	Gastrointestinal Pharmacology. 2017 ,		8
119	Adherence and Persistence Across Antidepressant Therapeutic Classes: A Retrospective Claims Analysis Among Insured US Patients with Major Depressive Disorder (MDD). 2017 , 31, 421-432		42
118	Biochemical effects of venlafaxine on astrocytes as revealed by H NMR-based metabolic profiling. 2017 , 13, 338-349		5
117	Mood Disorders. 2017 , 39-59		
116	5-HT modulation of pain perception in humans. 2017 , 234, 2929-2939		27
115	Factors Influencing the Cardiovascular Response to Subanesthetic Ketamine: A Randomized, Placebo-Controlled Trial. <i>International Journal of Neuropsychopharmacology</i> , 2017 , 20, 909-918	5.8	33
114	Response to duloxetine in chronic low back pain: exploratory post hoc analysis of a Japanese Phase III randomized study. <i>Journal of Pain Research</i> , 2017 , 10, 2157-2168	2.9	3
113	Absence of Claudin 11 in CNS Myelin Perturbs Behavior and Neurotransmitter Levels in Mice. 2018 , 8, 3798		15
112	Comparative pharmacology and toxicology of tramadol and tapentadol. 2018 , 22, 827-844		47

111	Visual hallucination induced by duloxetine use: a male case diagnosed with generalized anxiety disorder. 2018 , 28, 346-348		0
110	Antidepressant Therapy for Depression: An Update. 2018 , 241-255		
109	What Contributes to Serotonin-Norepinephrine Reuptake Inhibitors' Dual-Targeting Mechanism? The Key Role of Transmembrane Domain 6 in Human Serotonin and Norepinephrine Transporters Revealed by Molecular Dynamics Simulation. 2018 , 9, 1128-1140		139
108	Medications for alcohol use disorders: An overview. 2018 , 185, 64-85		37
107	Steroidogenic disruptive effects of the serotonin-noradrenaline reuptake inhibitors duloxetine, venlafaxine and tramadol in the H295R cell assay and in a recombinant CYP17 assay. 2018 , 47, 63-71		8
106	Nonopioid strategies for managing chronic pain. 2018 , 24, 47-61		2
105	Cancer Pain. 2018 , 17-35		
104	Effects of noradrenergic and serotonergic systems on risk-based decision-making and center arena activity in open field in rats. <i>European Journal of Pharmacology</i> , 2018 , 841, 57-66	53	7
103	New Antidepressant Medication: Benefits Versus Adverse Effects. 2018 ,		
102	The activity of brain and liver cytochrome P450 2D (CYP2D) is differently affected by antidepressants in the chronic mild stress (CMS) model of depression in the rat. 2018 , 156, 398-405		13
101	Molecular basis of atypicality of bupropion inferred from its receptor engagement in nervous system tissues. 2018 , 235, 2643-2650		4
100	Antidepressants-related cardiovascular adverse events using the adverse event reporting system. 2018 , 268, 441-446		4
99	Is There a Potential of Misuse for Venlafaxine and Bupropion?. 2018 , 9, 239		18
98	Abuse of Prescription Drugs in the Context of Novel Psychoactive Substances (NPS): A Systematic Review. 2018 , 8,		34
97	The risk of glaucoma and serotonergic antidepressants: A systematic review and meta-analysis. 2018 , 241, 63-70		8
96	Cardiovascular Safety of Psychiatric Agents: A Cautionary Tale. 2019 , 70, 103-129		10
95	Clinical characteristics associated with therapeutic nonadherence of the patients with major depressive disorder: A report on the National Survey on Symptomatology of Depression in China. 2019 , 25, 215-222		6
94	Cortical 5-hydroxytryptamine 1A receptor biased agonist, NLX-101, displays rapid-acting antidepressant-like properties in the rat chronic mild stress model. 2019 , 33, 1456-1466		14

93 Peripheral Diabetic Neuropathies. **2019**, 809-823

92 Serotonin Reuptake Inhibitors and Their Role in Chronic Pain Management. **2019**,

91 Relapse prevention with levomilnacipran ER in adults with major depressive disorder: A multicenter, randomized, double-blind, placebo-controlled study. **2019**, 36, 225-234 4

90 Antidepressants and nose-to-brain delivery: drivers, restraints, opportunities and challenges. **2019**, 24, 1911-1923 12

89 Long-lasting analgesic effect of the psychedelic drug changa: A case report. **2019**, 3, 7-13 2

88 Antidepressants affect gut microbiota and *Ruminococcus flavefaciens* is able to abolish their effects on depressive-like behavior. **2019**, 9, 133 67

87 Long-term follow-up of a patient with venlafaxine-induced diurnal bruxism treated with an occlusal splint: A case report. **2019**, 7, 516-524 2

86 Application of Biomedical Engineering in Neuroscience. **2019**,

85 CYP1A2 Genetic Polymorphism Is Associated With Treatment Remission to Antidepressant Venlafaxine in Han Chinese Population. *Clinical Neuropharmacology*, **2019**, 42, 32-36 1.4 2

84 Prevalence and risk factors of excessive daytime sleepiness in major depression: A study with 703 individuals referred for polysomnography. **2019**, 243, 23-32 18

83 Some Prospective Alternatives for Treating Pain: The Endocannabinoid System and Its Putative Receptors GPR18 and GPR55. **2018**, 9, 1496 40

82 Effectiveness of Venlafaxine in Selective Serotonin Reuptake Inhibitor-Resistant Obsessive-Compulsive Disorder: Experience From a Specialty Clinic in India. *Journal of Clinical Psychopharmacology*, **2019**, 39, 82-85 1.7 4

81 Managing fibromyalgia syndrome in pregnancy no bridges between USA and EU. **2019**, 22, 711-721 2

80 Duloxetine plasma level and antidepressant response. *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, **2019**, 92, 127-132 5.5 17

79 Noradrenaline reuptake inhibition increases control of impulsive action by activating D-like receptors in the infralimbic cortex. *European Journal of Pharmacology*, **2019**, 844, 17-25 5.3 7

78 Psychiatric Medication Use and Weight Outcomes One Year After Bariatric Surgery. *Psychosomatics*, **2020**, 61, 56-63 2.6 11

77 Association Between Side Effects and Blood microRNA Expression Levels and Their Targeted Pathways in Patients With Major Depressive Disorder Treated by a Selective Serotonin Reuptake Inhibitor, Escitalopram: A CAN-BIND-1 Report. *International Journal of Neuropsychopharmacology*, **2020**, 23, 88-95 5.8 5

76 Management Strategies for Spinal Cord Injury Pain Updated for the Twenty-First Century. *Physical Medicine and Rehabilitation Clinics of North America*, **2020**, 31, 369-378 2.3 1

75	Can wastewater analysis be used as a tool to assess the burden of pain treatment within a population?. <i>Environmental Research</i> , 2020 , 188, 109769	7.9	7
74	Venlafaxine-induced damage to seminiferous epithelium, spermiation, and sperm parameters in rats: A correlation with high estrogen levels. <i>Andrology</i> , 2021 , 9, 297-311	4.2	3
73	Medically Unexplained Symptoms. 2021 ,		1
72	Neuropharmacological and antidepressant-like effects of ZY-1408: A novel serotonin/norepinephrine reuptake inhibitor and serotonin receptor 2C antagonist. <i>Neuropharmacology</i> , 2021 , 182, 108376	5.5	1
71	Influence of Different Antidepressants on Ocular Surface in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021 , 41, 49-52	1.7	3
70	Roscoe Rhizomes Attenuate Oxaliplatin-Induced Neuropathic Pain in Mice. <i>Molecules</i> , 2021 , 26,	4.8	6
69	Meta-Analysis: Hemodynamic Responses to Sub-anesthetic Doses of Ketamine in Patients With Psychiatric Disorders. <i>Frontiers in Psychiatry</i> , 2021 , 12, 549080	5	3
68	Antidepressants and Risk of Sudden Cardiac Death: A Network Meta-Analysis and Systematic Review. <i>Medical Sciences (Basel, Switzerland)</i> , 2021 , 9,	3.3	2
67	Nano-Aromatic Drugs Based on Mesoporous Silica Nanoparticles and Bergamot Essential Oil for Anti-Depression. <i>Journal of Biomedical Nanotechnology</i> , 2021 , 17, 1242-1248	4	1
66	Involvement of Serotonergic System in Oxaliplatin-Induced Neuropathic Pain. <i>Biomedicines</i> , 2021 , 9,	4.8	2
65	Impact of duloxetine on male fertility: A randomised controlled clinical trial. <i>Andrologia</i> , 2021 , 53, e14207.4		0
64	Advances in Depression Management. <i>Advances in Psychiatry and Behavioral Health</i> , 2021 , 1, 185-203		
63	Antidepressant Drugs: Mechanisms of Action and Side Effects. 2022 , 613-626		
62	Psychopharmacologic agents (antidepressants, antipsychotics, anxiolytics, and psychostimulants) used in chronic pain. 129-144		1
61	Kontrolluntersuchungen unter Therapie mit Psychopharmaka. 2010 , 451-464		0
60	Pharmacometric Analyses to Support Early Development Decisions for LY2878735: A Novel Serotonin Norepinephrine Reuptake Inhibitor. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2013 , 2, e66	4.5	3
59	Efficacy of Desvenlafaxine Compared With Placebo in Major Depressive Disorder Patients by Age Group and Severity of Depression at Baseline. <i>Journal of Clinical Psychopharmacology</i> , 2017 , 37, 182-192 ^{1.7}	1.7	6
58	The dubious effect of milnacipran for the treatment of burning mouth syndrome. <i>Clinical Neuropharmacology</i> , 2011 , 34, 170-3	1.4	11

57	Prevalence of antidepressant prescription or use in patients with acute coronary syndrome: a systematic review. <i>PLoS ONE</i> , 2011 , 6, e27671	3.7	20
56	Does evidence support the American Heart Association's recommendation to screen patients for depression in cardiovascular care? An updated systematic review. <i>PLoS ONE</i> , 2013 , 8, e52654	3.7	90
55	Japanese experience with milnacipran, the first serotonin and norepinephrine reuptake inhibitor in Japan. <i>Neuropsychiatric Disease and Treatment</i> , 2007 , 3, 41-58	3.1	2
54	Sigma-1 receptor chaperones and diseases. <i>Central Nervous System Agents in Medicinal Chemistry</i> , 2009 , 9, 184-9	1.8	95
53	Considerations in the treatment of geriatric depression: Overview of pharmacotherapeutic and psychotherapeutic treatment interventions. <i>Research in Gerontological Nursing</i> , 2010 , 3, 176-86	1.6	14
52	Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial. <i>primary care companion for CNS disorders, The</i> , 2013 , 15,	1.2	2
51	Depression treatment in patients with coronary artery disease: a systematic review. <i>primary care companion for CNS disorders, The</i> , 2013 , 15,	1.2	12
50	A review of vilazodone, serotonin, and major depressive disorder. <i>primary care companion for CNS disorders, The</i> , 2014 , 16,	1.2	10
49	The desire for death in the setting of terminal illness: a case discussion. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2006 , 8, 299-305		16
48	More questions than answers! Clinical dilemmas in psychopharmacology in pregnancy and lactation. <i>Indian Journal of Psychiatry</i> , 2009 , 51, 26-33	2.2	3
47	Reduction of Methylphenidate Induced Anxiety, Depression and Cognition Impairment by Various doses of Venlafaxine in Rat. <i>International Journal of Preventive Medicine</i> , 2015 , 6, 52	1.6	18
46	Possible Role of Cyclic AMP Response Element Binding/Brain-Derived Neurotrophic Factor Signaling Pathway in Mediating the Pharmacological Effects of Duloxetine against Methamphetamine Use-Induced Cognitive Impairment and Withdrawal-Induced Anxiety and Depression. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2012 , 37, 11	1.2	7
45	Increased chromogranin a and carcinoid syndrome-like symptoms in a patient treated with duloxetine. <i>Endocrine Practice</i> , 2014 , 20, e215-8	3.2	2
44	Uncontrolled self-medication with venlafaxine in a patient with major depressive disorder. <i>Psychiatry Investigation</i> , 2011 , 8, 74-6	3.1	7
43	Comparison of pharmacological profiles of serotonin norepinephrine reuptake inhibitors. <i>Clinical Neuropsychopharmacology and Therapeutics</i> , 2010 , 1, 10-15	0.2	1
42	Antidepressants as Analgesics. 2008 , 643-657		
41	Generalized Anxiety Disorder. 2008 , 183-193		
40	Cambio en la intensidad del dolor con venlafaxina administrada de forma abierta en pacientes con sintomatología depresiva: estudio de observación en la atención primaria. <i>European Psychiatry (Ed Española)</i> , 2008 , 15, 298-307		

39	Milnacipran, a serotonin and norepinephrine reuptake inhibitor: a novel treatment for fibromyalgia. <i>International Journal of Clinical Rheumatology</i> , 2009 , 4, 507-517	1.5	
38	Venlafaxine for depression and glossovulvodynia: a case report. <i>Primary Care Companion To the Journal of Clinical Psychiatry</i> , 2010 , 12,		
37	Adjunctive Analgesics. 2012 , 171-187		
36	NCAM140 and pCREB Expression after Tianeptine Treatment of SH-SY5Y Cells. <i>Psychiatry Investigation</i> , 2014 , 11, 313-8	3.1	
35	The Role of Antidepressants in the Treatment of Chronic Pain. 2015 , 43-50		
34	Comparison of venlafaxine and duloxetine: measuring clinical impact of time to therapeutic dose (TTD) among patients achieving therapeutic dosing for pain. <i>Pharmacy & Pharmacology International Journal</i> , 2018 , 6,	0.7	
33	Anxiety, Stress, and Neurological Dysfunction: From Basic Biology to Present Therapeutic Interventions. 2019 , 401-413		
32	Melanonychia induced by venlafaxine hydrochloride. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2019 , 154, 495-496	0.8	0
31	Antidepressants In General Practice And Psychiatry. <i>European Journal of Medical and Health Sciences</i> , 2020 , 2,	2	0
30	Treatment of Psychosomatic Symptoms. 2021 , 177-198		
29	Pathogenetic mechanisms of antinociceptive activity of antidepressants. <i>Pharmacy Formulas</i> , 2020 , 2, 70-83	0.2	
28	Tolerability of High-Dose Venlafaxine After Switch From Escitalopram in Nonresponding Patients With Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021 , 41, 62-66	1.7	3
27	Milnacipran and venlafaxine at flexible doses (up to 200 mg/day) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomized, double-blind exploratory study. <i>Neuropsychiatric Disease and Treatment</i> , 2010 , 6, 71-9	3.1	2
26	Hepatotoxic effects with high-dose venlafaxine. <i>Psychiatry</i> , 2006 , 3, 10-1		1
25	Duloxetine for the management of fibromyalgia syndrome. <i>Journal of Pain Research</i> , 2009 , 2, 99-108	2.9	13
24	SNRIs pharmacological alternatives for the treatment of obsessive compulsive disorder?. <i>Innovations in Clinical Neuroscience</i> , 2011 , 8, 10-4	1	2
23	Suprathreshold duloxetine for treatment-resistant depression, anorexia nervosa binge-purging type, and obsessive-compulsive disorder: a case report. <i>Innovations in Clinical Neuroscience</i> , 2012 , 9, 13-6 ¹		1
22	A Randomized, Double-blind, Placebo-controlled Trial of the Efficacy and Safety of Levomilnacipran ER 40-120mg/day for Prevention of Relapse in Patients with Major Depressive Disorder. <i>Innovations in Clinical Neuroscience</i> , 2014 , 11, 10-22	1	10

21	Serotonin norepinephrine reuptake inhibitors: a pharmacological comparison. <i>Innovations in Clinical Neuroscience</i> , 2014 , 11, 37-42	1	10
20	Nanotherapeutics for Nose-to-Brain Drug Delivery: An Approach to Bypass the Blood Brain Barrier.. <i>Pharmaceutics</i> , 2021 , 13,	6.4	4
19	Novel Pharmacological Approaches to the Treatment of Depression.. <i>Life</i> , 2022 , 12,	3	4
18	Serotonin Receptors and Antidepressants: Neuroimaging Findings from Preclinical and Clinical Research. <i>NeuroMethods</i> , 2022 , 373-429	0.4	
17	Early Optimized Pharmacological Treatment in Patients With Depression and Chronic Pain.. <i>CNS Spectrums</i> , 2022 , 1-40	1.8	
16	Psychological and Psychopharmacological Interventions in Psychocardiology.. <i>Frontiers in Psychiatry</i> , 2022 , 13, 831359	5	2
15	A systematic review of pharmacologic treatment efficacy for depression in older patients with cancer.. <i>Brain, Behavior, & Immunity - Health</i> , 2022 , 21, 100449	5.1	3
14	Off-Target Effects of Antidepressants on Vascular Function and Structure.. <i>Biomedicines</i> , 2021 , 10,	4.8	0
13	Synthesis and evaluation of variably substituted N-methyl tetrahydroisoquinolines and benzazepines as monoamine reuptake inhibitors. <i>Results in Chemistry</i> , 2022 , 4, 100352	2.1	0
12	Pharmacological treatment of major depressive disorder according to severity in psychiatric inpatients: results from the AMSP pharmacovigilance program from 2001-2017.. <i>Journal of Neural Transmission</i> , 2022 , 1	4.3	0
11	Weight-centric treatment of depression and chronic pain. 2022 , 100025		0
10	The molecular pathophysiology of depression and the new therapeutics. <i>MedComm</i> , 2022 , 3,	2.2	1
9	Safety and Effectiveness of Desvenlafaxine in Korean Patients with Major Depressive Disorder: A 6-month Postmarketing Surveillance Study. <i>Clinical Psychopharmacology and Neuroscience</i> , 2022 , 20, 548-559	3.4	0
8	The Development and Mechanism of Treatment of Depression. 8, 133-142		
7	Pharmacological effects and therapeutic potential of natural compounds in neuropsychiatric disorders: An update. 13,		1
6	Determination of potential nitrosamines NDMA, NDIPA and N-Nitroso Duloxetine in Duloxetine Hydrochloride by LC-MS/MS using APCI source. 2022 ,		0
5	Past and current drug repurposing clinical trials to treat cognition in methamphetamine use: a scoping review of pharmacotherapy candidates. 2023 , 100064		0
4	A multicenter, randomized, double-blind, duloxetine-controlled, non-inferiority trial of desvenlafaxine succinate extended-release in patients with major depressive disorder. 2023 , 329, 72-80		0

- 3 Clinical outcomes of recommended active pharmacotherapy agents from NICE guideline for post-traumatic stress disorder: Network meta-analysis. **2023**, 125, 110754 ○
- 2 Depression, Angststörungen, bipolare Störung, Schizophrenie, Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom. **2022**, 451-495 ○
- 1 Current Opinions about the Use of Duloxetine: Results from a Survey Aimed at Psychiatrists. **2023**, 13, 333 ○